The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCerillion Regulatory News (CER)

Share Price Information for Cerillion (CER)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,570.00
Bid: 1,550.00
Ask: 1,590.00
Change: -10.00 (-0.63%)
Spread: 40.00 (2.581%)
Open: 1,545.00
High: 1,570.00
Low: 1,545.00
Prev. Close: 1,580.00
CER Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Offer Update

17 Dec 2007 08:16

OAO Severstal17 December 2007 Not for release, publication or distribution, in whole or in part, in, into or from Canada, South Africa, Japan or any other jurisdiction where it would be unlawful to do so. 17 December 2007 RECOMMENDED REVISED CASH OFFER BY CENTROFERVE LIMITED A WHOLLY OWNED SUBSIDIARY OF SEVERSTAL FOR CELTIC RESOURCES HOLDINGS PLC OFFER UNCONDITIONAL IN ALL RESPECTS Centroferve, a wholly owned subsidiary of Severstal, announces that Condition(b) to the Offer, which is set out in Part A (Conditions of the Revised Offer)of Appendix I to the Revised Offer Document, has been satisfied and that,accordingly, the Offer is unconditional in all respects. Celtic Shareholders who have accepted or accept the Offer while it remains openfor acceptance will receive aggregate cash consideration of £2.90 per CelticShare. Settlement of the consideration to which an accepting Celtic Shareholderis entitled under the Offer will be effected in the following manner: • in the case of acceptances of the Revised Offer received, valid and complete in all respects, prior to the date of this announcement, within 14 days of the date of this announcement; or • in the case of acceptances of the Revised Offer received, valid and complete in all respects, after the date of this announcement but while the Offer remains open for acceptance, within 14 days of such receipt. Celtic Shareholders who have not yet accepted the Offer and wish to do so shouldcomplete a Form of Acceptance and return it to Capita Registrars (by post, toCapita Registrars, PO Box 7117, Dublin 2, Ireland or, during normal businesshours only, by hand to Capita Registrars, Unit 5, Manor Street Business Park,Manor Street, Dublin 7, Ireland) as soon as possible. The Offer will remain open for acceptance until 3.00pm (Dublin time) on 30January 2008. Centroferve will now procure that Celtic Resources Holdings plc applies forcancellation of the trading of Celtic Shares to take effect on 17 January 2008.Cessation of trading will significantly reduce the liquidity and marketabilityof any Celtic Shares in respect of which acceptances of the Offer are notsubmitted. Having received acceptances of the Offer in respect of more than 80% of theCeltic Shares to which the Offer relates, Centroferve will shortly send outnotices pursuant to the provisions of Section 204 of the Companies Act 1963informing those holders of Celtic Shares who have not yet validly accepted theOffer of its intention to acquire compulsorily all outstanding Celtic Shares towhich the Offer relates on the same terms as the Offer. As at 3.00 p.m. on Friday 14 December 2007, acceptances of the Offer had beenreceived in respect of 47,266,133 Celtic Shares (representing approximately 84.7% of the Celtic Shares to which the Offer relates). Centroferve did not hold any Celtic Shares before the commencement of the OfferPeriod and has not acquired or agreed to acquire any Celtic Shares during theOffer Period. Prior to the Offer Period, Bluecone, a company owned by Severstal,acquired 12,281,946 Celtic Shares, and during the Offer Period (but before theOriginal Offer was made) Bluecone acquired a further 4,301,056 Celtic Shares. Asa result, Bluecone owns 16,583,002 Celtic Shares representing approximately29.7% of the issued share capital of Celtic, and the acceptances referred toabove include an acceptance of the Offer by Bluecone in respect of all of theCeltic Shares held by Bluecone. Other than the Celtic Shares held or acquired byBluecone, no party acting in concert with Centroferve held before thecommencement of the Offer Period, or acquired or agreed to acquire during theOffer Period, any Celtic Shares. Terms defined in the Revised Offer Document dated 20 November 2007 have the samemeaning in this announcement unless otherwise stated. Enquiries: Centroferve Tel: +7 495 9810 910 ext.6633Roman DeniskinNikolai Zelenski Morgan Stanley & Co. Limited Tel: +44 20 7425 8000Peter BacchusArash Mahdaviani FD London Tel: +44 207 831 3113Jon SimmonsBen Brewerton The directors of Centroferve and the directors of Severstal acceptresponsibility for the information contained in this announcement. To the bestof the knowledge and belief of the directors of Centroferve and the directors ofSeverstal (who have taken all reasonable care to ensure that such is the case),the information contained in this announcement for which they acceptresponsibility is in accordance with the facts and does not omit anything likelyto affect the import of such information. Morgan Stanley & Co. Limited ("Morgan Stanley") is acting exclusively forCentroferve and Severstal Resurs and no one else in connection with the Offerand Morgan Stanley will not regard any other person as a client in relation tothe Offer and will not be responsible to anyone other than Centroferve andSeverstal Resurs for providing the protections afforded exclusively to itsclients or for providing advice in relation to the Offer, the contents of thisannouncement or any transaction or arrangement referred to herein. The Offer will not be made, directly or indirectly, in or into any jurisdictionwhere it would be unlawful to do so, or by use of the mails, or by any means orinstrumentality (including, without limitation, telephonically orelectronically) of interstate or foreign commerce, or by any facility of anational securities exchange of any jurisdiction where it would be unlawful todo so, and the Offer will not be capable of acceptance by any such means,instrumentality or facility from or within any jurisdiction where it would beunlawful to do so. Accordingly, copies of this announcement and all otherdocuments relating to the Offer are not being, and must not be, mailed orotherwise forwarded, distributed or sent in, into or from any jurisdiction whereit would be unlawful to do so. Persons receiving such documents (including,without limitation, nominees, trustees and custodians) should observe theserestrictions. Failure to do so may invalidate any related purported acceptanceof the Offer. Notwithstanding the foregoing restrictions, Centroferve reservesthe right to permit the Offer to be accepted if, in its sole discretion, it issatisfied that the transaction in question is exempt from or not subject to thelegislation or regulation giving rise to the restrictions in question. This announcement does not constitute an offer to sell or an invitation topurchase or the solicitation of an offer to purchase or subscribe for anysecurities. Any response in relation to the Offer should be made only on thebasis of the information contained in the Revised Offer Document or any documentby which the Offer is made. Any person who is a holder of 1% or more of the Celtic Shares may havedisclosure obligations under Rule 8.3 of the Takeover Rules, effective from thedate of the commencement of the Offer Period. The Offer will be made in the United States pursuant to an exemption from the UStender offer rules provided by Rule 14d-1(c) under the US Exchange Act. Notice to US holders of Celtic Shares: The Offer will be made for the securities of an Irish public limited companywhose shares are listed on the AIM market in the UK and is subject to Irish andUK disclosure requirements, which are different from those of the United States.The Offer will be made in the United States pursuant to applicable US tenderoffer rules and otherwise in accordance with the requirements of the IrishTakeover Rules. Accordingly, the Offer will be subject to disclosure and otherprocedural requirements, including with respect to withdrawal rights, offertimetable, settlement procedures and timing of payments that are different fromthose applicable under US domestic tender offer procedures and law. The receipt of cash pursuant to the Offer by a US holder of Celtic Shares may bea taxable transaction for US federal income tax purposes and under applicable USstate and local, as well as foreign and other tax laws. Each holder of CelticShares is urged to consult his independent professional adviser immediatelyregarding the tax consequences of acceptance of the Offer. It may be difficult for US holders of Celtic Shares to enforce their rights andany claim arising out of the US federal securities laws, since Centroferve andCeltic are located in non-US jurisdictions, and some or all of their officersand directors may be residents of non-US jurisdictions. US holders of CelticShares may not be able to sue a non-US company or its officers or directors in anon-US court for violations of the US securities laws. Further, it may bedifficult to compel a non-US company and its affiliates to subject themselves toa US court's judgement. In accordance with normal Irish and UK practice and pursuant to Rule 14e-5(b) ofthe US Exchange Act, Centroferve or its nominees, or its brokers (acting asagents), may from time to time make certain purchases of, or arrangements topurchase, Celtic Shares outside the United States, other than pursuant to theOffer, before or during the period in which the Offer remains open foracceptance. These purchases may occur either in the open market at prevailingprices or in private transactions at negotiated prices. Any information aboutsuch purchases will be disclosed as required in Ireland and the UK, will bereported to a Regulatory Information Service of the UK Listing Authority andwill be available on the London Stock Exchange website,www.londonstockexchange.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Apr 20247:00 amRNSTrading Update
13th Mar 20247:00 amRNSShare Purchase
13th Feb 20245:27 pmRNSTR-1 Notification
13th Feb 20245:22 pmRNSTR-1
1st Feb 20243:30 pmRNSResult of AGM
15th Dec 20234:15 pmRNSPosting of Annual Report and Notice of AGM
21st Nov 20235:34 pmRNSPDMR Shareholding
20th Nov 20237:00 amRNSFinal Results
17th Nov 20237:00 amRNSNotice of Results and Online Presentation
7th Nov 20237:00 amRNSLatest product release incorporates Generative AI
2nd Nov 20237:00 amRNSMajor new customer win with Tier-1 Telco
16th Oct 20237:00 amRNSTrading Update
25th Sep 202311:53 amRNSHolding(s) in Company
6th Jul 20237:00 amRNSCompletion of Initial Implementation at Telesur
21st Jun 20237:00 amRNSMajor new contract
22nd May 20237:00 amRNSGartner Market Guide Reports
15th May 20237:00 amRNSHalf-year Report
4th May 20237:00 amRNSDate of Interim Results and Investor Presentation
17th Apr 20237:00 amRNSH1 2023 Trading Update
31st Mar 20237:00 amRNSMajor New Contract
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
14th Mar 20232:32 pmRNSHolding(s) in Company
21st Feb 20237:00 amRNSCompletion of Major Implementation
2nd Feb 20232:19 pmRNSResult of AGM
20th Jan 20234:40 pmRNSSecond Price Monitoring Extn
20th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20227:00 amRNSGrant of Options and PDMR Shareholding
15th Dec 20225:20 pmRNSHolding(s) in Company
2nd Dec 20222:35 pmRNSHolding(s) in Company
30th Nov 20226:29 pmRNSPDMR and PCA shareholding
30th Nov 202211:18 amRNSHolding(s) in Company
28th Nov 20227:00 amRNSFinal Results
23rd Nov 20227:00 amRNSNotice of Results and Investor Presentation
2nd Nov 20225:49 pmRNSHolding(s) in Company
2nd Nov 202212:40 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSRelease of latest version of flagship product set
24th Oct 20227:00 amRNSTrading Update
6th Oct 20227:00 amRNSAppointment of Joint Broker
25th Aug 20223:48 pmRNSGrant of Options
8th Aug 20223:08 pmRNSHolding(s) in Company
28th Jul 20224:35 pmRNSPrice Monitoring Extension
19th Jul 20227:00 amRNSHolding(s) in Company
6th Jul 20227:00 amRNSMajor Contract Win
13th May 20227:33 amRNSDirector Share Purchase
9th May 20227:00 amRNSInterim Results Presentation
9th May 20227:00 amRNSInterim Results
25th Apr 202210:13 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSH1 2022 Trading Update
6th Apr 20227:00 amRNSCerillion Client MVN-X Reaches Million Subscribers
7th Mar 20227:00 amRNSWins Prestigious Megabuyte Performance Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.